AKT1 and endometrial cancer: For instance, METTL3 decreases the expression of PHLPP2 (a negative AKT regulator) and increases the expression of mTORC2 (a positive AKT regulator) to stimulate AKT activation and suppress tumorigenesis and invasion in endometrial cancer [10].